J. Goldman & CO LP Vertex Pharmaceuticals Inc Transaction History

J. Goldman & CO LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$407.69 - $446.08 $1.73 Million - $1.89 Million	4,236 New	4,236 $1.77 Million
Q2 2023 Aug 14, 2023	BUY	$314.42 - $351.91 $550,235 - $615,842	1,750 New	1,750 $615,000
Q4 2022 Feb 14, 2023	BUY	$285.76 - $321.48 $8.62 Million - $9.7 Million	30,168 New	30,168 $8.71 Million
Q2 2022 Aug 15, 2022	SELL	$234.96 - $292.55 $2.81 Million - $3.5 Million	-11,970 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$221.42 - $260.97 $1.49 Million - $1.75 Million	6,708 Added 127.48%	11,970 $3.12 Million
Q4 2021 Feb 14, 2022	BUY	$177.01 - $223.45 $931,426 - $1.18 Million	5,262 New	5,262 $1.16 Million
Q2 2021 Aug 16, 2021	SELL	$187.49 - $221.1 $5.53 Million - $6.52 Million	-29,508 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$207.02 - $241.31 $6.11 Million - $7.12 Million	29,508 New	29,508 $6.34 Million

1,707

226M

1.2M

1.59M

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $122B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

Get notified when there are updates to the investment portfolio of J. Goldman & CO LP, based on Form 13F filings with the SEC.

Stay updated on J. Goldman & CO LP with notifications on news.